Groundbreaking Oral Weight-Loss Pill Foundayo Gets FDA Approval
Eli Lilly's new GLP-1 tablet Foundayo becomes the second FDA-approved oral weight-loss medication, offering a convenient alternative to injectable treatments.
Foundayo, a pioneering oral weight-loss medication developed by pharmaceutical giant Eli Lilly, has just received the coveted green light from the US Food and Drug Administration (FDA). This momentous approval marks the second GLP-1 drug in pill form to hit the market, following on the heels of Novo Nordisk's Wegovy which was approved late last year.
The once-daily Foundayo tablet offers a convenient alternative to the injectable GLP-1 weight-loss medications that have gained popularity in recent years. This new oral formulation provides patients with a simpler, more accessible option to manage their weight and improve their overall health.
{{IMAGE_PLACEHOLDER}}Source: The Guardian
